An Open-label, Randomized Three Period Cross-over Relative Bioavailability Study to Compare the Pharmacokinetic Parameters of a Lower Dose Formulation of Ambrisentan (GSK1325760) With Marketed Ambrisentan in Healthy Adult Participants
Latest Information Update: 06 Sep 2023
At a glance
- Drugs Ambrisentan (Primary)
- Indications Pulmonary arterial hypertension; Pulmonary hypertension
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 17 Jan 2020 Status changed from recruiting to completed.
- 06 Dec 2019 Planned End Date changed from 15 Dec 2019 to 16 Dec 2019.
- 06 Dec 2019 Planned primary completion date changed from 15 Dec 2019 to 16 Dec 2019.